ClinicalTrials.gg
CompletedNCT06247735Updated Oct 7, 2026

Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.

A Phase 2 interventional study of K-808 (Dose A) and K-808 (Dose B) in Primary Biliary Cholangitis, sponsored by Kowa Research Institute, Inc.. Completed at 38 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Kowa Research Institute, Inc. (part of Kowa Company, Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 4 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jun 2026.
Updated Oct 7, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies in Liver Cirrhosis, Biliary with a site in United States — 11 open to participants now, 18 under way, 8 of them phase 3. Liver Cirrhosis, Biliary · United States.

Enrollment
33rd of 65
46 · median 46
Started
2024
with 6 others
Phase 2
34 of 83
2 open now
Registered
70th of 83
by date
Lead sponsor
2 of 83
Kowa Research Institute, Inc.

Among the 83 studies in Liver Cirrhosis, Biliary with a site in United States, this one is the 33rd largest by enrollment of the 65 interventional ones that give a count, is one of 7 that started in 2024, is one of 34 in phase 2, and was the 70th registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

11 of the 83 studies in Liver Cirrhosis, Biliary with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Liver Cirrhosis, Biliary with a site in United States, or all of them as a file.
02

Study summary

Study to investigate the efficacy and safety of two doses of K-808 (pemafribate) in subjects with PBC.

03

Conditions studied

  • Primary Biliary Cholangitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participant who has a PBC diagnosis as demonstrated by the presence of ≥2 of the following three diagnostic criteria:

    • History of ALP above for at least 6 months
    • History of positive antimitochondrial antibody (AMA) titer or positive PBC-specific antinuclear antibody (ANA) titer
    • Historical liver consistent with PBC
  • Participant has the following qualifying biochemistry value at Screening:

    • ALP ≥1.5 × ULN
  • Participant is ≥18 years of age at consent.
  • Participant meets all other eligibility criteria outlined in the Clinical Study Protocol.

Exclusion criteria

Exclusion Criteria:

  • Participant meets any one of the following criteria at Screening:

    • ALP>10 ×
    • or AST >5 × ULN
    • treatment within 5 years of Screening, or active hepatitis C as defined by positive hepatitis C antibody with the presence of hepatitis C virus ribonucleic acid; subjects with active (HBV) infection (hepatitis B surface antigen [HbsAg] positive) will be excluded. A subject with resolved hepatitis A at least 3 months prior to the Screening Visit can be screened.
    • Primary sclerosing cholangitis and secondary sclerosing cholangitis (eg, due to cholangiolithiasis, ischemia, telangiectasia, vasculitis, infectious diseases)
    • Alcoholic liver disease
    • History of definite hepatitis or PBC/autoimmune hepatitis overlap, defined as both of the following: 1) IgG >2 × ULN and/or positive anti-smooth muscle antibodies, 2) liver histology revealing moderate or severe periportal or periseptal inflammation
    • Nonalcoholic steatohepatitis (NASH)
    • Gilbert's Syndrome
    • Alpha-1-antitrypsin deficiency, cystic fibrosis, Wilson's disease, hemochromatosis based on historically established diagnosis
    • Drug-induced liver injury (DILI) as defined by typical exposure and history
    • Known condition that involves bile duct obstruction or cholestasis other than PBC, eg, vascular diseases (eg, Budd-Chiari syndrome, sinusoidal obstruction syndrome, congestive hepatopathy), congenital conditions (ductal plate malformations, Caroli syndrome, congenital liver fibrosis), idiopathic ductopenia
    • Hepatocellular carcinoma
  • Participant meets any other exclusion criteria outlined in the Clinical Study Protocol.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
46 participants (actual)

Study arms

  • Placebo comparator
    Placebo + K-808 (Group A)

    Placebo for 12 Weeks followed by K-808 (Dose A) for 52 Weeks

    Drug: K-808 (Dose A) · Drug: Placebo

  • Placebo comparator
    Placebo + K-808 (Group B)

    Placebo for 12 Weeks followed by K-808 (Dose B) for 52 Weeks

    Drug: K-808 (Dose B) · Drug: Placebo

  • Experimental
    K-808 Group A

    K-808 (Dose A) for 64 Weeks

    Drug: K-808 (Dose A)

  • Experimental
    K-808 Group B

    K-808 (Dose B) for 64 Weeks

    Drug: K-808 (Dose B)

Interventions

  • Administered orally once daily

    Also known as: Pemafibrate

  • Administered orally once daily

    Also known as: Pemafibrate

  • DrugPlacebo

    Administered orally once daily

06

What researchers measure

Primary outcomes

  1. Percent change from baseline in serum alkaline phosphatase (ALP)

    Two doses of K-808 compared to placebo after 12 weeks of treatment

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Achievement of normalization of ALP level

    ALP ≤1 × upper limit of normal (ULN)

    Time frame: Baseline to Week 12

  2. Achievement of target levels of ALP and total bilirubin (TB)

    After two doses of K-808

    Time frame: Baseline to Weeks 12 and 64

  3. Change from baseline in liver function parameters

    liver function test results including ALP, total and conjugated bilirubin, albumin, international normalized ratio \[INR\], γ-GT, ALT, AST, albumin, platelets count

    Time frame: Baseline to Weeks 12 and 64

  4. Change from baseline in GLOBE risk score

    calculated by GLOBE scoring system which is calculated based on serum values of bilirubin, ALP, albumin and platelet count.

    Time frame: Baseline to Weeks 12 and 64

  5. Change from baseline in UK-PBC score

    PBC risk score developed by United Kingdom (UK)-PBC Consortium is a scoring system and the calculation is based on laboratory test measurements and upper limits of normal (ULN) for the total bilirubin (BIL12); alanine transaminase or aspartate transaminase (TA12), and alkaline phosphatase (ALP12) after at least 12 months of UDCA, and the laboratory test measurements and lower limits of normal (LLN) for the serum albumin and platelet count in the same timeframe. A high number is indicative of a worse score.

    Time frame: Baseline to Weeks 12 and 64

  6. Incidence of Treatment Emergent Adverse Events (TEAEs)

    Coded using the most recent version of Medical Dictionary of Regulatory Activities (MedDRA).

    Time frame: Baseline to Week 68

07

Study locations

38 sites
  • UA Thomas D. Boyer Liver Institute
    Tucson, Arizona 85724, United States
  • Southern California Research Center - Coronado
    Coronado, California 92118, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Velocity Clinical Research
    Santa Ana, California 92704, United States
  • Peak Gastroenterology Associates Colorado Springs
    Colorado Springs, Colorado 80921, United States
  • University of Florida Hepatology Research at CTRB
    Gainesville, Florida 32610, United States
  • Florida Research Institute
    Lakewood Rch, Florida 34211, United States
  • University of Miami Leonard M. Miller School of Medicine
    Miami, Florida 33136, United States
  • Springfield Clinic
    Springfield, Illinois 62702, United States
  • Mercy Medical Center - Mcauley Plaza
    Baltimore, Maryland 21202, United States
  • CommonSpirit Health Research Institute
    Omaha, Nebraska 68124, United States
  • New York University Hepatology Associates
    New York, New York 10016, United States
  • Wake Forest University Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • Einstein Medical Center
    Philadelphia, Pennsylvania 19141, United States
  • Rapid City Medical Center
    Rapid City, South Dakota 57701, United States
  • Vanderbilt Digestive Disease Center
    Nashville, Tennessee 37232, United States
  • Pioneer Research Solutions
    Houston, Texas 77099, United States
  • UVA Health - University of Virginia Health System
    Charlottesville, Virginia 22908, United States
  • Gastrointestinal and Liver Specialists of Tidewater - Digestive and Liver Disease Specialists
    Norfolk, Virginia 23502, United States
  • Liver Institute Northwest
    Seattle, Washington 98105, United States
  • (G.I,R,I) GI Research Institute
    Vancouver, British Columbia V6Z 2K5, Canada
  • Office of Dr. Gauthier
    North Bay, Ontario P1B 2H3, Canada
  • Toronto General Hospital
    Toronto, Ontario M5G 2C4, Canada
  • Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM)
    Montreal, Quebec H2X 0A9, Canada
  • 306
    Fukui, Japan
  • 313
    Fukuoka, Japan
  • 305
    Hamamatsu, Japan
  • 308
    Hirakata, Japan
  • 309
    Hiroshima, Japan
  • 304
    Isehara, Japan
  • 303
    Itabashi-ku, Japan
  • 312
    Kanazawa, Japan
  • 307
    Matsumoto, Japan
  • 311
    Ōmura, Japan
  • 302
    Sapporo, Japan
  • Teine Keijinkai Hospital
    Sapporo, Japan
  • 314
    Yokohama, Japan
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Jun 2025, 16 months.

Of 21 phase 2 interventional studies under Liver Cirrhosis, Biliary, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 34. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2024
First posted
Feb 8, 2024
StartActual
Feb 7, 2024
Primary completionActual
Jun 26, 2025
CompletionActual
Jul 23, 2026
Results delay requested
Jun 24, 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Jul 22, 2026→Jul 23, 2026
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Study completion Jul 22, 2026→Jul 23, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06247735
Responsible party
Sponsor
First posted
Feb 8, 2024
Start date
Feb 7, 2024
Primary completion
Jun 26, 2025
Completion
Jul 23, 2026
Last update
Oct 7, 2026

Study contacts

Andre Belous, MD, PhD
study director · Kowa Pharma Development Co.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemafibrate

Start the discussion